The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Predicting IMiD sensitivity in myeloma
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses research currently being performed to allow for the prediction of individual multiple myeloma patient’s responses to drugs, particularly lenalidomide and pomalidomide. Dr Fonseca speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, and explains how flow cytometry assays that measure oxidative stress relief were used in the study to predict sensitivity to immunomodulatory imide drugs (IMIDs).
